Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Multiple Myeloma, Autoimmune Disease, and Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD38 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD38 ECD-Fc Fusion Protein (wild-type & mutant available). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW verified. | View CD38 Products |
| Gene Delivery | CD38 Promise-ORF / Lentivirus. Full-length ORF lentiviral particles for stable cell line generation. High titer >10^8 TU/mL, Puromycin selection. | View CD38 Products |
| Benchmark Ab | Anti-CD38 (Sequence of Daratumumab & Isatuximab). Recombinant human IgG1κ positive control. Sequence Verified. | View CD38 Products |
| Validator | CD38 siRNA Set. For target knockdown verification (knockdown efficiency >70%). | View CD38 Products |
| Related Target A | BCMA (TNFRSF17). Synergistic target for Multiple Myeloma combinations and bispecific designs. Current clinical co-target. | View BCMA Products |
| Related Target B | SLAMF7 (CS1). Established myeloma target; orthogonal mechanism to CD38 in immune cell activation. | View SLAMF7 Products |
| Related Target C | GPRC5D. Resistance bypass target for CD38-refractory patients; emerging in bispecifics. | View GPRC5D Products |
| Related Target D | CD138 (Syndecan-1). Plasma cell marker, co-targeting strategy for multiple myeloma. | View CD138 Products |
| Related Target E | CD157 (BST1). Homologous protein (50% homology), critical for selectivity screening to avoid off-target toxicity. | View CD157 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse toxicology evaluation | Human / Cyno / Mouse CD38 ortholog proteins available; >95% purity; Sequence Verified by Mass Spectrometry for epitope conservation mapping. |
| Conformational epitope preservation | Native glycosylation via HEK293 expression ensures identical structural folding to endogenous receptors, crucial for conformational binding. |
| Subfamily counter-screening (CD157/BST1 off-target) | CD38 vs CD157 protein panel (mass spec verified) for strict off-target liability screening. Conformational epitope binding assay ready. |
| Lack of clinical positive controls | Anti-CD38 benchmark antibodies (Daratumumab & Isatuximab biosimilar sequences); Recombinant, endotoxin-controlled. |
| False positive binding in primary screens | Validated CD38 siRNA set included for knockdown specificity confirmation in cell-based assays. |
| Internalization & ADC payload delivery feasibility | High-purity CD38 ECD-Fc preserves native glycosylation for receptor-mediated endocytosis assay development. pH-sensitive conjugation validation. |
| Surface expression validation for cell-based assays | CD38 Lentivirus for stable cell line generation preserving native conformation (Flow Cytometry validated expression). |
Live CD38 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD38 therapeutics is intensifying, with major players shifting focus from traditional intravenous mAbs to subcutaneous co-formulations and next-generation multispecific modalities. As first-generation therapies (Daratumumab, Isatuximab) expand into earlier lines of multiple myeloma and penetrate autoimmune indications (SLE, MG), the next wave of R&D is targeting relapsed/refractory settings. Key trends include: (1) optimizing bispecific engagement (e.g., CD38xCD3) with affinity tuning to reduce CRS; (2) overcoming CD38 downregulation resistance via epitope-engineered variants and combination with ATRA; (3) expanding into solid tumors through ADCs and CAR-T; (4) addressing the emerging CD38 mutation (UniProt VAR_001323) that reduces activity by 50% and contributes to type II diabetes risk, which may impact patient stratification and biomarker development.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (naked mAb) | Janssen (Daratumumab), Sanofi (Isatuximab), I-MAB (Felzartamab) | Multiple Myeloma, AL Amyloidosis, SLE | ADCC/ADCP/CDC assays requiring high-purity Fc-competent antigen and stable cell lines (HEK293-expressed ECD, lentivirus). |
| Bispecific T-cell Engager (CD38xCD3) | Johnson & Johnson, Roche, Regeneron, AbbVie (TNB-383B) | Relapsed/Refractory MM, Autoimmune | Heterodimer validation & affinity tuning; cross-reactivity panel (CD38 vs CD157 selectivity); T-cell activation reporters. |
| ADC / Radioligand Therapy | Takeda (TAK-573), BioNTech (BNT114), Sorrento | Solid tumors (lung, breast), Hematologic malignancies | Internalization assay (pH-sensitive trafficking); high-purity ECD-Fc for binding kinetics; conjugation validation. |
| CAR-T Therapy | Novartis, Poseida Therapeutics, Academic centers | Advanced MM | Epitope specificity & activation; lentivirus for stable target cell lines (native conformation). |
Key Mutations & Resistance Mechanisms
CD38 exhibits a clinically relevant mutation (UniProt P28907 VAR_001323) that reduces enzymatic activity by approximately 50% and is associated with increased susceptibility to type II diabetes. This mutation may affect antibody binding epitopes and internalization dynamics, necessitating mutant protein reagents for screening. Additionally, prolonged anti-CD38 therapy leads to CD38 downregulation; combination strategies and next-generation modalities targeting alternative epitopes or co-targets (BCMA, GPRC5D) are under active development.
Conclusion
TarMart provides a comprehensive, high-purity reagent ecosystem covering wild-type and mutant CD38 proteins, lentiviral gene delivery, benchmark antibodies, and off-target panels to support every stage of CD38 drug discovery—from target validation to preclinical safety assessment.